Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Voyager Therapeutics

3.27
-0.1200-3.54%
Volume:37.10K
Turnover:123.50K
Market Cap:201.49M
PE:-1.80
High:3.40
Open:3.39
Low:3.26
Close:3.39
52wk High:5.55
52wk Low:2.94
Shares:61.62M
Float Shares:44.40M
Volume Ratio:1.35
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8121
EPS(LYR):-2.0400
ROE:-54.09%
ROA:-27.34%
PB:1.31
PE(LYR):-1.60

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Voyager Therapeutics
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
141
Office Location:
75 Hayden Avenue,Lexington,Massachusetts,United States
Website:
http://www.voyagertherapeutics.com
Zip Code:
02421
Phone:
857 259 5340
Fax:
- -
Introduction:
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Directors

Name
Position
Alfred Sandrock
Chief Executive Officer and Director and President
Michael Higgins
Chairman of the Board and Director
Catherine J. Mackey
Director
George Scangos
Director
Glenn Pierce
Director
Grace E. Colon
Director
James Arthur Geraghty
Director
Jude Onyia
Director
Nancy Vitale
Director
Steven Hyman
Director

Shareholders

Name
Position
Alfred Sandrock
Chief Executive Officer and Director and President
Robin Swartz
Principal Financial Officer, Treasurer, Chief Business Officer and Chief Operating Officer
Gregory Shiferman
General Counsel and Secretary and Senior Vice President
Amy Quinlan
Principal Accounting Officer
Todd Carter
Chief Scientific Officer